BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary ...
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. The BSA-based method of dose calculation was adopted without adequate investigation of its ...
Multiple Courses of High-Dose Ifosfamide, Carboplatin, and Etoposide With Peripheral-Blood Progenitor Cells and Filgrastim for Small-Cell Lung Cancer: A Feasibility Study by the European Group for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results